journal article·2023-03

Dressing Bacteria With a Hybrid Immunoactive Nanosurface to Elicit Dual Anticancer and Antiviral Immunity

Ying Liu, Mengmeng Zhang, Xinyue Wang, Fengmin Yang, Zhenping Cao, Lu Wang, Jinyao Liu

Advanced Materials· Volume 35· Issue 11
Publisher page

Abstract

Abstract Approaches capable of simultaneously treating cancer and protecting susceptible patients from lethal infections such as coronavirus disease 2019, are highly desirable but prove to be difficult. Here, dressing bacteria with a hybrid immunoactive nanosurface is reported to elicit dual anticancer and antiviral immunity. A combination of a checkpoint blocking antibody and a virus‐specific antigen is covalently conjugated to polydopamine nanoparticles, which can be anchored onto bacterial surface, by a one‐step in situ polymerization of dopamine under a cell‐friendly condition. By virtue of the ability to colonize and penetrate deep tumor tissue, dressed bacteria enable sustained release and expanded exposure of carried immunoactivators to stimulate immune cells. In addition to a carrier role, bacteria are able to further provoke innate immunity due to the native immunogenicity of the pathogen‐associated molecular patterns. Immunization with dressed bacteria promotes the maturation, and activation of antigen‐presenting cells, which induces robust humoral and cellular immune responses in tumor‐bearing mice. As evidenced by efficient production of viral‐antigen‐specific immunoglobulin G antibody in serum and significantly suppressed tumor growth in different models, dressing bacteria with a hybrid immunoactive nanosurface paves an avenue to prepare next‐generation therapeutics for synergistic treatment and prevention.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer Research and Treatments · Bacteriophages and microbial interactions · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine Institute of Molecular Medicine Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai 200127 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (56)

Show source-provided references
1. 10.3322/caac.2149210.3322/caac.21492 ↗
2. 10.1038/s41591-020-0979-010.1038/s41591-020-0979-0 ↗
3. 10.1016/S1473-3099(13)70154-310.1016/S1473-3099(13)70154-3 ↗
4. 10.1002/cncr.2014110.1002/cncr.20141 ↗
5. 10.1056/NEJMp200376210.1056/NEJMp2003762 ↗
6. 10.1016/j.immuni.2015.09.00110.1016/j.immuni.2015.09.001 ↗
7. 10.1186/s13045-022-01307-210.1186/s13045-022-01307-2 ↗
8. 10.1038/ni.203910.1038/ni.2039 ↗
9. 10.1038/s41590-022-01274-310.1038/s41590-022-01274-3 ↗
10. 10.1021/acsnano.8b0595010.1021/acsnano.8b05950 ↗
11. 10.1016/j.it.2017.10.00210.1016/j.it.2017.10.002 ↗
12. 10.1016/S1470-2045(20)30096-610.1016/S1470-2045(20)30096-6 ↗
13. 10.1007/s11864-021-00903-710.1007/s11864-021-00903-7 ↗
14. 10.1038/nrc293410.1038/nrc2934 ↗
15. 10.1002/advs.20200357210.1002/advs.202003572 ↗
16. 10.1111/j.1600-065X.1997.tb01002.x10.1111/j.1600-065X.1997.tb01002.x ↗
17. 10.1002/adma.20210024110.1002/adma.202100241 ↗
18. 10.1038/nbt125610.1038/nbt1256 ↗
19. 10.1038/cmi.2008.1110.1038/cmi.2008.11 ↗
20. 10.1002/adma.20200737910.1002/adma.202007379 ↗
21. 10.1002/advs.20180058110.1002/advs.201800581 ↗
22. 10.1016/j.cell.2020.02.05810.1016/j.cell.2020.02.058 ↗
23. 10.1126/science.abb276210.1126/science.abb2762 ↗
24. 10.1126/science.abb250710.1126/science.abb2507 ↗
25. 10.1126/science.abc628410.1126/science.abc6284 ↗
26. 10.1016/S0140-6736(20)31604-410.1016/S0140-6736(20)31604-4 ↗
27. 10.1038/s41467-020-20653-810.1038/s41467-020-20653-8 ↗
28. 10.1002/jmv.2632010.1002/jmv.26320 ↗
29. 10.1016/j.jconrel.2017.10.04110.1016/j.jconrel.2017.10.041 ↗
30. 10.1007/978-1-0716-0795-4_2510.1007/978-1-0716-0795-4_25 ↗
31. 10.1016/j.mehy.2010.12.01010.1016/j.mehy.2010.12.010 ↗
32. 10.1111/1751-7915.1352310.1111/1751-7915.13523 ↗
33. 10.1038/s41467-018-03233-910.1038/s41467-018-03233-9 ↗
34. 10.1158/1078-0432.CCR-07-425410.1158/1078-0432.CCR-07-4254 ↗
35. 10.1038/s41573-021-00345-810.1038/s41573-021-00345-8 ↗
36. 10.1002/adma.20210666910.1002/adma.202106669 ↗
37. 10.1016/j.nantod.2021.10128010.1016/j.nantod.2021.101280 ↗
38. 10.1021/cr400407a10.1021/cr400407a ↗
39. 10.1038/mt.2011.5710.1038/mt.2011.57 ↗
40. 10.1146/annurev.immunol.18.1.76710.1146/annurev.immunol.18.1.767 ↗
41. 10.7150/thno.3513110.7150/thno.35131 ↗
42. 10.1093/annonc/mdx23710.1093/annonc/mdx237 ↗
43. 10.1038/cr.2016.15710.1038/cr.2016.157 ↗
44. 10.1038/s41568-018-0070-z10.1038/s41568-018-0070-z ↗
45. 10.1016/j.nantod.2022.10153710.1016/j.nantod.2022.101537 ↗
46. 10.1016/j.immuni.2022.03.00710.1016/j.immuni.2022.03.007 ↗
47. 10.1172/JCI9658210.1172/JCI96582 ↗
48. 10.1039/D0CC06959K10.1039/D0CC06959K ↗
49. 10.1371/journal.ppat.100229310.1371/journal.ppat.1002293 ↗
50. 10.1016/j.immuni.2020.11.00910.1016/j.immuni.2020.11.009 ↗
51. 10.1016/j.cell.2020.05.01510.1016/j.cell.2020.05.015 ↗
52. 10.1038/s41577-021-00537-810.1038/s41577-021-00537-8 ↗
53. 10.1002/jcb.2754710.1002/jcb.27547 ↗
54. 10.3109/0891060090344426710.3109/08910600903444267 ↗
55. 10.1016/j.tcb.2020.06.00310.1016/j.tcb.2020.06.003 ↗
56. 10.1002/adma.20190296010.1002/adma.201902960 ↗